Clinical trial
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
NCT00352066 · Avexa, Industry · Completed
Key facts
| NCT number | NCT00352066 |
|---|---|
| Title | Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together |
| Official title | A Phase I, Open Label, Controlled, Intra-subject Comparison Study to Investigate the Effect of Co-administration Upon the Pharmacokinetics of Tipranavir (Ritonavir Boosted) and Apricitabine. |
| Lead sponsor | Avexa, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | apricitabine |
| Enrollment | 18 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jul 14, 2006 |
| Last update posted | Jun 23, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: